At present, ACT is mostly carried out in hematological malignancies, while CAR-T cell technology has also been conducted in sarcoma targeting ERBB2/HER2, renal cell carcinoma targeting carbonic anhydrase, and cholangiocarcinoma targeting epidermal growth factor (Rohaan et al., 2019). The gene discussed is ERBB2; the disease is hereditary clear cell renal cell carcinoma.